Cosmetic ingredient and drug company Sirona Biochem names chief business development officer

30-Oct-2014 - Last updated on 30-Oct-2014 at 15:42 GMT

Attila Hajdu, previously of GlaxoSmithKline and Astellas Pharma, joins Sirona Biochem where he’ll work to build new partnership and identify products likely to become strong revenue-generating assets.

Hajdu, who holds degrees from Queen’s University and the University of Western Ontario, comes to the company with extensive experience assessing the viability of biochemical and pharma projects as well as liaising with global executives to establish relationships with leading companies.

“It is critical that we align ourselves with the needs of our potential partners and the market to reach the next level. Having a skilled leader in business development with a proven track record is imperative and we are very confident that Attila can meet the company’s needs,” said Dr. Howard Verrico, CEO of Sirona Biochem.

New leaders

Hajdu isn’t the only new c-suite executive at the cosmetic ingredient company. In June of this year Howard Verrico became CEO when Neil Belenkie resigned from the position.

The company has financial backing concerns, Verrico acknowledged in an open letter at the time. This latest hiring addresses that directly.